Copenhagen, November 8, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the company expects to publish financial reports according to the following schedule:

Deadline for submission of shareholder proposals to Annual General Meeting

February 12, 2019


Annual Report 2018

March 1, 2019


Annual General Meeting 2019

March 27, 2019


Interim Report First Half 2019

August 28, 2019


The financial reports will upon their release be available at the Company's website,, where information relating to Orphazyme's Annual General Meeting 2019 will also be available in due course prior to the meeting.